These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 29175677)

  • 41. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
    Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
    Unseld M; Drimmel M; Siebenhüner A; Gleiss A; Bianconi D; Kieler M; Scheithauer W; Winder T; Prager GW
    Clin Colorectal Cancer; 2018 Dec; 17(4):274-279. PubMed ID: 30042010
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry.
    Kopeckova K; Buchler T; Bortlicek Z; Hejduk K; Chloupkova R; Melichar B; Pokorna P; Tomasek J; Linke Z; Petruzelka L; Kiss I; Prausova J
    Target Oncol; 2017 Feb; 12(1):89-95. PubMed ID: 27638381
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regorafenib: A Review in Hepatocellular Carcinoma.
    Heo YA; Syed YY
    Drugs; 2018 Jun; 78(9):951-958. PubMed ID: 29915898
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer.
    Komori A; Taniguchi H; Hamauchi S; Masuishi T; Kito Y; Narita Y; Tsushima T; Ishihara M; Todaka A; Tanaka T; Yokota T; Kadowaki S; Machida N; Ura T; Fukutomi A; Ando M; Onozawa Y; Tajika M; Yasui H; Muro K; Mori K; Yamazaki K
    Oncology; 2017; 93(5):329-335. PubMed ID: 28866662
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Propensity Score Weighting Using Overlap Weights: A New Method Applied to Regorafenib Clinical Data and a Cost-Effectiveness Analysis.
    Mlcoch T; Hrnciarova T; Tuzil J; Zadak J; Marian M; Dolezal T
    Value Health; 2019 Dec; 22(12):1370-1377. PubMed ID: 31806193
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Multikinase inhibitor regorafenib offers an efficient therapeutic alternative].
    Rev Med Suisse; 2014 May; 10(431):1108. PubMed ID: 24941678
    [No Abstract]   [Full Text] [Related]  

  • 48. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy.
    Angeles A; Hung W; Cheung WY
    Med Oncol; 2018 Jun; 35(8):114. PubMed ID: 29936654
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Regorafenib in metastatic colorectal cancer.
    Sartore-Bianchi A; Zeppellini A; Amatu A; Ricotta R; Bencardino K; Siena S
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):255-65. PubMed ID: 24559322
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study.
    Nakashima M; Ide K; Kawakami K
    Target Oncol; 2019 Jun; 14(3):295-306. PubMed ID: 31093834
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort.
    Metges JP; Genet D; Tougeron D; Ligeza C; Ducreux M; Borg C; Guimbaud R; Phelip JM; Dourthe LM; Kim S
    Future Oncol; 2021 Sep; 17(25):3343-3353. PubMed ID: 34011165
    [No Abstract]   [Full Text] [Related]  

  • 52. Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
    Sueda T; Sakai D; Kudo T; Sugiura T; Takahashi H; Haraguchi N; Nishimura J; Hata T; Hayashi T; Mizushima T; Doki Y; Mori M; Satoh T
    Anticancer Res; 2016 Aug; 36(8):4299-306. PubMed ID: 27466548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review.
    Xie X; Zhang J; Hu H; Cai Y; Wu Z; Ling J; Li W; Deng Y
    Adv Ther; 2020 Oct; 37(10):4233-4248. PubMed ID: 32770529
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report.
    Yoshino K; Manaka D; Kudo R; Kanai S; Mitsuoka E; Kanto S; Hamasu S; Konishi S; Nishitai R
    J Med Case Rep; 2017 Aug; 11(1):227. PubMed ID: 28818109
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.
    Pavlakis N; Sjoquist KM; Martin AJ; Tsobanis E; Yip S; Kang YK; Bang YJ; Alcindor T; O'Callaghan CJ; Burnell MJ; Tebbutt NC; Rha SY; Lee J; Cho JY; Lipton LR; Wong M; Strickland A; Kim JW; Zalcberg JR; Simes J; Goldstein D
    J Clin Oncol; 2016 Aug; 34(23):2728-35. PubMed ID: 27325864
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial.
    Pasqualetti G; Schirripa M; Dochy E; Fassan M; Ziranu P; Puzzoni M; Scartozzi M; Alberti G; Lonardi S; Zagonel V; Monzani F; Loupakis F
    Eur J Cancer; 2020 Jul; 133():66-73. PubMed ID: 32446145
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
    Shirley M; Keating GM
    Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
    Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
    Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention and management of adverse events related to regorafenib.
    De Wit M; Boers-Doets CB; Saettini A; Vermeersch K; de Juan CR; Ouwerkerk J; Raynard SS; Bazin A; Cremolini C
    Support Care Cancer; 2014 Mar; 22(3):837-46. PubMed ID: 24337717
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
    Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.